Cagrilintide
- 1 lab in 1 country
Outcomes
2Adverse events
upin humans1
1 study
Adverse events
upin humans1
Cagrilintide increases adverse events in humans.
Human trialversus placebo
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo
Annals of medicine and surgery (2012)13 Jul 2026
Body weight
downin humans1
1 study
Body weight
downin humans1
Cagrilintide decreases body weight in humans (MD: -6.08%, MD: -5.89 kg).
Human trialversus placebo
Amylin-based obesity therapy: a meta-analysis of Cagrilintide and CagriSema versus placebo
Annals of medicine and surgery (2012)13 Jul 2026
Trials
30In trials
Phase 3Completed22 trials
Phase 3Completed12 trials
Phase 3Completed8 trials
Phase 3Active, not recruiting1 trial
Phase 2Completed1 trial
Chronic renal insufficiency
Phase 2Completed1 trial
All 7Fewer
Hepatic impairment
Phase 1Completed1 trial
Readouts due
- 12 May 2027
Phase 3Active, not recruiting
- 1 Sept 2027
Development
- Companies
- Novo NordiskPhase 3overweight, obesity
Trial sponsors
Company24 trialsPhase 321,202 people